enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Adalimumab - Wikipedia

    en.wikipedia.org/wiki/Adalimumab

    Adalimumab, sold under the brand name Humira and others, is a disease-modifying antirheumatic drug and monoclonal antibody used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis.

  3. UnitedHealth to remove AbbVie's Humira from some US drug ...

    www.aol.com/news/unitedhealth-remove-abbvies...

    The U.S. market share for Humira biosimilars stands at nearly 20%, compared with 2.2% in the first quarter of this year, Barclays analysts said in a note on Monday.

  4. AIDS Drug Assistance Programs - Wikipedia

    en.wikipedia.org/wiki/AIDS_Drug_Assistance_Programs

    The program first began in 1987 with appropriations to help pay for AZT. The program was expanded in 1990 with the Ryan White Comprehensive AIDS Resources Emergency (CARE) Act (commonly referred to as the Ryan White Care Act. [1] Most recipients are below 200% of the Federal Poverty Level (FPL) and 43 percent are below 100% the FPL.

  5. Expanded access - Wikipedia

    en.wikipedia.org/wiki/Expanded_access

    Expanded access or compassionate use is the use of an unapproved drug or medical device under special forms of investigational new drug applications (IND) or IDE application for devices, outside of a clinical trial, by people with serious or life-threatening conditions who do not meet the enrollment criteria for the clinical trial in progress.

  6. Pharmaceutical industry - Wikipedia

    en.wikipedia.org/wiki/Pharmaceutical_industry

    Phase II can include pharmacokinetics and dosing in patients, and Phase III is a very large study of efficacy in the intended patient population. Following the successful completion of Phase III testing, a New Drug Application is submitted to the FDA. The FDA reviews the data and if the product is seen as having a positive benefit-risk ...

  7. Teva CEO says not too late to launch Humira biosimilar in 2024

    www.aol.com/news/teva-ceo-says-not-too-162604893...

    Francis said Teva's Iceland production site still needs to pass an inspection before it gets U.S. Food and Drug Administration approval, likely in the first half of 2024.

  8. Upadacitinib - Wikipedia

    en.wikipedia.org/wiki/Upadacitinib

    Upadacitinib, sold under the brand name Rinvoq, is a medication used for the treatment of rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, and axial spondyloarthritis.